Roundtable Discussion: Refining Biomarkers for Earlier Indication of Treatment Response to Predict Phase 2/3 Success
- Examine the limitations of current biomarkers like eGFR and albuminuria in predicting late-stage trial outcomes.
- Explore novel functional and molecular biomarkers that could better indicate clinical success in phase three.
- Address the challenges of long and large CKD trials by integrating predictive biomarkers to shorten timelines and refine patient selection.
- Discuss strategies to align biomarker discovery with emerging targets to increase translational confidence and probability of success